Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel + prednisone
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cabazitaxel + prednisone is a combination regimen used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with a docetaxel-containing regimen. Cabazitaxel is a second-generation semisynthetic taxane and microtubule inhibitor that binds to beta-tubulin subunits, stabilizing microtubules and preventing their disassembly. This action disrupts mitosis and inhibits tumor cell proliferation. Unlike earlier taxanes such as docetaxel and paclitaxel, cabazitaxel has low affinity for the P-glycoprotein efflux pump, allowing it to overcome certain drug resistance mechanisms and cross the blood-brain barrier[1][6][8]. Prednisone is an oral corticosteroid administered daily during cabazitaxel therapy to help manage side effects and possibly enhance antitumor activity[1][3]. The combination was developed by Sanofi and first approved by the FDA in 2010 for this indication[5][8].
- Other names
- cabazitaxelprednisone
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel + prednisone.